Companies /Healthcare

Alimera Sciences Inc

NASDAQ: ALIM Drug Manufacturers - Specialty & Generic
$5.54
â–² $0.00 (+0.00%) today
Markets closed · 7:26pm ET
Today · % change

Fundamentals

Market Cap
$301.3M
P/E Ratio
5.3
Profit Margin
-14.7%
Revenue (TTM)
$99.7M
EPS (TTM)
$1.05
Street Target
$5.67

About ALIM

Alimera Sciences Inc is a pharmaceutical company focused on creating treatments for eye diseases. Its main product, ILUVIEN, is an implant designed to treat diabetic macular edema, a condition that can lead to severe vision loss in people with diabetes. The company markets its products mainly to healthcare providers like physician offices and hospitals, both in the United States and internationally. Founded in 2003 and based in Alpharetta, Georgia, Alimera Sciences also collaborates on projects to expand its treatment offerings for various eye conditions.

ALIM Coverage

9:30am ET
Health and Healthcare

pSivida, Alimera and Ariad Join Bio-Implosion Watch

ThinkstockBiotech and emerging health care technology companies both fit into a high-stake poker match on Wall Street. Investors can earn exponential rewards if they are right, or they can lose it all…

Jon C. Ogg
10:28am ET
Investing

Morning Movers (ALIM, TBET, ODP, PEIX, APOL)

The three major US equities indexes opened flat this morning following a poor report on durable goods orders (more coverage here) and a new low for the Case-Shiller home price index (more…

Paul Ausick